Hyperbaric Oxygen Therapy for Retinal Vein Occlusion: What the Evidence Shows

Important: Hyperbaric oxygen therapy is not FDA-approved for retinal vein occlusion (CRVO or BRVO). This is an investigational use. The published evidence is preliminary. Insurance will not cover HBOT for this condition. All costs are out-of-pocket.

If you were diagnosed with a retinal vein occlusion and then found this site’s page on retinal artery occlusion, it’s easy to assume hyperbaric oxygen is a cleared option for your eye too. It isn’t. The approved retinal indication is central retinal artery occlusion, a different problem with a different cause. Vein occlusion is common, distressing, and managed mainly by a retina specialist, and the case for HBOT here rests on a handful of small reports rather than the kind of trial data that supports the artery use.

Vein Occlusion Is Not Artery Occlusion

The two conditions get confused constantly, partly because the names look alike and partly because both cause vision changes in one eye. The mechanics are opposite.

A central retinal artery occlusion blocks blood flowing into the retina. Oxygen supply stops, and the tissue starts dying within roughly 90 to 100 minutes. That is why it’s treated as a stroke of the eye and why our page on retinal artery occlusion frames it as an emergency. CRAO is a recognized hyperbaric indication and a Medicare-covered use, which is exactly what vein occlusion is not.

A retinal vein occlusion blocks the drainage of blood out of the retina. The arteries keep pushing blood in, but it can’t leave, so pressure backs up. The result is swelling (macular edema), small hemorrhages, and sometimes leakage of fluid that distorts central vision. It develops over hours to days rather than minutes, and it ranges from mild blurring to significant loss depending on whether the central vein (CRVO) or a single branch vein (BRVO) is affected, and on whether the occlusion is ischemic or non-ischemic.

Because the underlying problem is different, the treatment is different. A blockage you cannot drain is not fixed by flooding the tissue with extra oxygen the way an artery blockage might be bridged.

What Standard Care Looks Like

This part matters because it is the comparison any HBOT claim has to be measured against. The American Academy of Ophthalmology’s Retinal Vein Occlusions Preferred Practice Pattern lists intravitreal anti-VEGF injections as the first-line treatment for the macular edema that drives vision loss in RVO. Two of those agents, ranibizumab and aflibercept, are FDA-approved for the indication, and bevacizumab is used off-label with supporting evidence. Intravitreal corticosteroids are an option, with their own risks of glaucoma and cataract, and laser photocoagulation is sometimes used for branch occlusions and for complications like neovascularization.

That care is delivered by a retina specialist, not a hyperbaric center. If you have a vein occlusion, an ophthalmologist who manages retinal disease is the person to see, and prompt evaluation matters because untreated macular edema can cause lasting damage.

What the HBOT Research Actually Says

The honest summary is that the evidence for hyperbaric oxygen in retinal vein occlusion is thin. It consists mostly of case reports and small case series, not randomized controlled trials, and that limits how much weight any single positive result can carry.

Johnson et al. (2019) reported a case series of six patients with central retinal artery or vein occlusion treated with hyperbaric oxygen. Three of the six, including the one CRVO patient, had near-complete recovery of vision (PMID: 31763582). That is an encouraging anecdote, but a series of six is not a controlled trial. There was no comparison group receiving standard care, so it cannot show whether HBOT changed the outcome or whether those patients would have improved anyway.

Several other published cases describe HBOT used in unusual situations, such as a central retinal vein occlusion occurring alongside a cilioretinal artery occlusion, where the artery component is the part with a recognized hyperbaric rationale. Narrative reviews of hyperbaric oxygen in ophthalmology note that HBOT has been tried in selected ischemic vein occlusions, while stating plainly that the supporting evidence is not strong and that regulators have not approved it for this use.

Reporting this fairly means not cherry-picking the favorable cases. Positive case reports get published and shared far more readily than disappointing ones, so a list of “successes” tells you little about how often HBOT helps or fails across everyone who tries it. Without a controlled trial, the benefit for vein occlusion remains unproven.

What This Means If You Have a Vein Occlusion

The practical takeaways are straightforward. HBOT is not an approved or insurance-covered treatment for retinal vein occlusion, so any course of it would be out-of-pocket at roughly $250 to $450 per session (rates change annually, verify with your facility’s billing team). The treatments with real evidence behind them, anti-VEGF injections and the other options your retina specialist may discuss, are the standard of care, and delaying them to pursue an unproven therapy carries its own risk.

If a clinic markets hyperbaric oxygen for retinal vein occlusion, ask them to show you the controlled evidence and to confirm in writing that insurance will not cover it. Our guide on questions to weigh before any off-label HBOT walks through how to evaluate that kind of offer.

Bring the question to the ophthalmologist managing your eye. They can tell you whether your occlusion is ischemic or non-ischemic, what your standard options are, and whether there is any reason to consider hyperbaric oxygen in your specific case.

Frequently Asked Questions

Is HBOT FDA-approved for retinal vein occlusion? No. Vein occlusion (CRVO and BRVO) is not a cleared hyperbaric indication. The approved retinal use is central retinal artery occlusion, a different condition.

Will insurance cover HBOT for a vein occlusion? No. Because it is not an approved indication, insurance and Medicare will not cover it, and all costs are out-of-pocket.

Is there any good evidence HBOT helps vein occlusion? Not at this point. The published reports are small case series and individual cases with no control group. There are no randomized controlled trials showing benefit for vein occlusion.

Should I delay anti-VEGF injections to try HBOT first? That is a question for your retina specialist, but the anti-VEGF approach is the treatment with established evidence for the macular edema in RVO. Pursuing an unproven therapy in its place can mean lost time during a window when standard care may help.

References

Johnson, D.R. et al. (2019). Retinal Artery and Vein Occlusions Successfully Treated with Hyperbaric Oxygen. Clinical Practice and Cases in Emergency Medicine. Case series of six patients (three improved, including the CRVO case). PMID: 31763582. https://pubmed.ncbi.nlm.nih.gov/31763582/

American Academy of Ophthalmology. Retinal Vein Occlusions Preferred Practice Pattern. Lists intravitreal anti-VEGF as first-line for RVO-related macular edema. https://www.aao.org/education/preferred-practice-pattern/retinal-vein-occlusions-ppp

Undersea and Hyperbaric Medical Society. Approved Indications for Hyperbaric Oxygen Therapy. Central retinal artery occlusion is listed, retinal vein occlusion is not. https://www.uhms.org/

Browse all conditions on the conditions hub. For the related and very different approved use, see the retinal artery occlusion page. Another brain-and-nerve investigational use is covered on the TBI and concussion page.

Medical Disclaimer: This page is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before pursuing any medical treatment.